MAM
NAGE

Martingale Asset Management’s Niagen Bioscience NAGE Stock Holding History

Martingale Asset Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,351
Closed -$84.9K – 875
2025
Q4 		$84.9K Buy
+13,351
New +$92.9K ﹤0.01% 765
2020
Q4 		– Sell
-120,925
Closed -$486K – 1058
2020
Q3 		$486K Sell
120,925
-80,300
-40% -$387K 0.01% 822
2020
Q2 		$924K Buy
+201,225
New +$901K 0.01% 752

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Martingale Asset Management's NAGE Position: Q1 2026 in Review

Martingale Asset Management sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 13,351 shares — an estimated $84.9K sold.

Martingale Asset Management first reported a position in NAGE in Q2 2020 and held it in 3 quarters. The position peaked at $924K in Q2 2020. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Martingale Asset Management reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Martingale Asset Management sold 13,351 Niagen Bioscience shares in Q1 2026, an estimated $84.9K.
  • Martingale Asset Management first reported a position in Niagen Bioscience in Q2 2020 and held it in 3 quarters.
  • Martingale Asset Management's Niagen Bioscience position peaked at $924K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.